In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Pfizer (PFE – Research Report). The company’s shares closed last Friday at $25.40.
According to TipRanks, Devarakonda is a 4-star analyst with an average return of 14.9% and a 49.30% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as Cytokinetics, Incyte, and Keros Therapeutics.
In addition to Truist Financial, Pfizer also received a Buy from Cantor Fitzgerald’s Louise Chen in a report issued on April 15. However, on April 22, Wells Fargo maintained a Hold rating on Pfizer (NYSE: PFE).
Based on Pfizer’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $14.25 billion and a GAAP net loss of $3.37 billion. In comparison, last year the company earned a revenue of $24.29 billion and had a net profit of $4.99 billion
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pfizer (PFE) Company Description:
Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Read More on PFE:
- Options Volatility and Implied Earnings Moves This Week, April 29 – May 02, 2024
- PFE Upcoming Earnings Report: What to Expect?
- Pfizer (NYSE:PFE) Notches Up on New FDA Approval
- Pfizer announces approval of BEQVE by FDA for adults with hemophilia B
- Pfizer call volume above normal and directionally bullish
